title: The National Institutes of Health and the Best Pharmaceuticals for Children Act.
abstract: The majority of drugs used to treat children are not labeled for use in children. The Best Pharmaceuticals for Children Act of 2002, re-authorized as the US FDA Amendments Act of 2007, directs the National Institutes of Health (NIH) to sponsor pediatric clinical trials of drugs lacking patent protection, if the FDA request for studies has been declined. The NIH is currently sponsoring 17 clinical studies. Challenges encountered include a paucity of investigators who are trained in pediatric clinical pharmacology; inadequate knowledge of the mechanisms of drug action in a growing child; and lack of pediatric formulations.
authors.affiliation: Center for Research for Mothers and Children, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-7510, USA. zajiceka@mail.nih.gov
authors.forename: Anne
authors.initials: A
authors.lastname: Zajicek
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic / Q000592:standards; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D033161:Government Regulation; D006801:Humans; D007223:Infant; D007880:Legislation, Drug; D009316:National Institutes of Health (U.S.); D010372:Pediatrics; D014481:United States; D014486:United States Food and Drug Administration